HHSN272201700082C

IGF::OT::IGF ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER

Research the contractor View USAspending source Save to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

Field	Reported value
Agency	Department of Health and Human Services
Office	NATIONAL INSTITUTES OF HEALTH NIAID
NAICS	541712
PSC	AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Parent award / vehicle	Not reported
Set-aside	NO SET ASIDE USED.
Pricing type	COST NO FEE
Obligations	$26.1M
Current contract value	$26.1M
Potential contract value / ceiling	$27.0M
Start date	Aug 31, 2017
Current end date	Jan 31, 2027
Potential end date	Jan 31, 2027
Latest award activity	Sep 4, 2025
Source loaded	Sep 26, 2026

Funding and modification history

Showing the latest 29 of 29 loaded transactions. Negative values are deobligations.

Date	Modification	Obligation change	Description
Sep 4, 2025	P00028	$-602.7K	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Oct 28, 2024	P00027	$3.3M	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Sep 26, 2024	P00026	$-209.8K	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Aug 16, 2024	P00025	$708.8K	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Jul 25, 2024	P00024	$0	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Feb 28, 2024	P00023	$-1.2M	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Feb 22, 2024	P00022	$27.2K	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Dec 15, 2023	P00021	$0	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Nov 8, 2023	P00020	$181.2K	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Sep 14, 2023	P00019	$-383.5K	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Apr 20, 2023	P00018	$589.2K	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Feb 16, 2023	P00016	$-257.7K	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Feb 16, 2023	P00017	$392.0K	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Aug 18, 2022	P00015	$2.8M	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Jun 21, 2022	P00014	$0	ADV DEVELOPMENT OF MULTIVALENT VACCINE
May 13, 2022	P00013	$0	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Jan 24, 2022	P00012	$610.7K	ADV DEVELOPMENT OF MULTIVALENT VACCINE
Oct 25, 2021	P00011	$0	EO14042 R&D - MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT
Aug 3, 2021	P00010	$1.3M	TASK AREA B
Jul 31, 2020	P00009	$4.5M	TASK AREA B
Feb 13, 2020	P00008	$0	TASK AREA B
Aug 5, 2019	P00007	$1.5M	TASK AREA B
Jan 24, 2019	P00006	$5.3M	IGF::OT::IGF ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER
Jul 26, 2018	5	$0	IGF::OT::IGF ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER
Jun 20, 2018	4	$2.2M	IGF::OT::IGF ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER
May 1, 2018	3	$0	IGF::OT::IGF ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER
Feb 7, 2018	2	$2.7M	IGF::OT::IGF ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER
Nov 27, 2017	1	$0	IGF::OT::IGF ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER
Aug 31, 2017	0	$2.6M	IGF::OT::IGF ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER

Estimated positioning window

Oct 25, 2026 – Jan 23, 2027

Recompete signal:

75/100

Why this recompete signal

Contract timing and recorded acquisition signals at the time of calculation.

Stored score: 75/100. Available recorded signals: 70 points.

Contract end 2027-01-31 (98 days from calculation): +35 points
31 historical awards in this buyer and category group: +15 points
29 recorded award transactions: +10 points
Latest award action: 2025-09-04: +0 points
Parent award identifier recorded: +0 points
Solicitation identifier recorded: +10 points
Linked official forecast: +0 points
Calculated on: 2026-10-25 10:18:04.631876+00:00

The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.

Rule-based research score; it does not measure your chance of winning.

This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.

USAspending award record

. Rule-based research score; positioning dates are estimates.

Recompete score calculated Oct 25, 2026.

Research next steps

Check the linked forecast or SAM for a confirmed solicitation and current timing.
Check the stated set-aside against the solicitation and current certifications.
Review the award scope and buyer evidence before making a bid/no-bid decision.